226 related articles for article (PubMed ID: 32559187)
1. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
[TBL] [Abstract][Full Text] [Related]
2. Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.
Lim SL; Damnernsawad A; Shyamsunder P; Chng WJ; Han BC; Xu L; Pan J; Pravin DP; Alkan S; Tyner JW; Koeffler HP
Haematologica; 2019 Jun; 104(6):1209-1220. PubMed ID: 30606790
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
4. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
5. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.
Zhang X; Lee HC; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Singh RK; Lu J; Qian Y; Raina K; Coleman KG; Crews CM; Li B; Wang H; Hailemichael Y; Thomas SK; Wang Z; Davis RE; Orlowski RZ
Leukemia; 2018 Oct; 32(10):2224-2239. PubMed ID: 29581547
[TBL] [Abstract][Full Text] [Related]
6. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.
Zhang H; Pandey S; Travers M; Sun H; Morton G; Madzo J; Chung W; Khowsathit J; Perez-Leal O; Barrero CA; Merali C; Okamoto Y; Sato T; Pan J; Garriga J; Bhanu NV; Simithy J; Patel B; Huang J; Raynal NJ; Garcia BA; Jacobson MA; Kadoch C; Merali S; Zhang Y; Childers W; Abou-Gharbia M; Karanicolas J; Baylin SB; Zahnow CA; Jelinek J; Graña X; Issa JJ
Cell; 2018 Nov; 175(5):1244-1258.e26. PubMed ID: 30454645
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
Manohar SM; Rathos MJ; Sonawane V; Rao SV; Joshi KS
Leuk Res; 2011 Jun; 35(6):821-30. PubMed ID: 21216463
[TBL] [Abstract][Full Text] [Related]
8. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
9. ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.
He L; Chen C; Gao G; Xu K; Ma Z
Aging (Albany NY); 2020 Mar; 12(5):4547-4557. PubMed ID: 32163373
[TBL] [Abstract][Full Text] [Related]
10. BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.
Winter GE; Mayer A; Buckley DL; Erb MA; Roderick JE; Vittori S; Reyes JM; di Iulio J; Souza A; Ott CJ; Roberts JM; Zeid R; Scott TG; Paulk J; Lachance K; Olson CM; Dastjerdi S; Bauer S; Lin CY; Gray NS; Kelliher MA; Churchman LS; Bradner JE
Mol Cell; 2017 Jul; 67(1):5-18.e19. PubMed ID: 28673542
[TBL] [Abstract][Full Text] [Related]
11. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
[TBL] [Abstract][Full Text] [Related]
12. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
Caracciolo V; Laurenti G; Romano G; Carnevale V; Cimini AM; Crozier-Fitzgerald C; Gentile Warschauer E; Russo G; Giordano A
Cell Cycle; 2012 Mar; 11(6):1202-16. PubMed ID: 22391209
[TBL] [Abstract][Full Text] [Related]
13. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
Blake DR; Vaseva AV; Hodge RG; Kline MP; Gilbert TSK; Tyagi V; Huang D; Whiten GC; Larson JE; Wang X; Pearce KH; Herring LE; Graves LM; Frye SV; Emanuele MJ; Cox AD; Der CJ
Sci Signal; 2019 Jul; 12(590):. PubMed ID: 31311847
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia.
Garcia-Cuellar MP; Füller E; Mäthner E; Breitinger C; Hetzner K; Zeitlmann L; Borkhardt A; Slany RK
Leukemia; 2014 Jul; 28(7):1427-35. PubMed ID: 24445865
[TBL] [Abstract][Full Text] [Related]
15. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
[TBL] [Abstract][Full Text] [Related]
16. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
[TBL] [Abstract][Full Text] [Related]
17. Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Álvarez-Fernández S; Ortiz-Ruiz MJ; Parrott T; Zaknoen S; Ocio EM; San Miguel J; Burrows FJ; Esparís-Ogando A; Pandiella A
Clin Cancer Res; 2013 May; 19(10):2677-87. PubMed ID: 23532886
[TBL] [Abstract][Full Text] [Related]
18. T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes.
Dow EC; Liu H; Rice AP
J Cell Physiol; 2010 Jul; 224(1):84-93. PubMed ID: 20201073
[TBL] [Abstract][Full Text] [Related]
19. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism.
Lu H; Xue Y; Yu GK; Arias C; Lin J; Fong S; Faure M; Weisburd B; Ji X; Mercier A; Sutton J; Luo K; Gao Z; Zhou Q
Elife; 2015 Jun; 4():e06535. PubMed ID: 26083714
[TBL] [Abstract][Full Text] [Related]
20. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
Saenz DT; Fiskus W; Qian Y; Manshouri T; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Mill CP; Sun B; Qiu P; Kadia TM; Pemmaraju N; DiNardo C; Kim MS; Nowak AJ; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Leukemia; 2017 Sep; 31(9):1951-1961. PubMed ID: 28042144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
